Sonoma Pharmaceuticals Enters Material Definitive Agreement

Ticker: SNOA · Form: 8-K · Filed: Mar 25, 2025 · CIK: 1367083

Sentiment: neutral

Topics: material-agreement, exhibits, financial-statements

TL;DR

Sonoma Pharma just signed a big deal, filing an 8-K with new agreements and financials.

AI Summary

Sonoma Pharmaceuticals, Inc. entered into a Material Definitive Agreement on March 21, 2025. The filing also includes financial statements and exhibits related to this agreement. The company, formerly known as Oculus Innovative Sciences, Inc., is incorporated in Delaware and headquartered in Boulder, Colorado.

Why It Matters

This filing indicates a significant new contract or partnership for Sonoma Pharmaceuticals, which could impact its future revenue and operations.

Risk Assessment

Risk Level: medium — Entering into a material definitive agreement can introduce new risks and opportunities, the specifics of which are not detailed in this initial filing.

Key Players & Entities

FAQ

What is the nature of the Material Definitive Agreement entered into by Sonoma Pharmaceuticals, Inc. on March 21, 2025?

The filing does not specify the details of the Material Definitive Agreement, only that one was entered into on March 21, 2025.

What other information is included in this 8-K filing besides the Material Definitive Agreement?

The filing also includes Financial Statements and Exhibits.

When was Sonoma Pharmaceuticals, Inc. previously known by another name?

Sonoma Pharmaceuticals, Inc. was formerly known as Oculus Innovative Sciences, Inc., with a date of name change on June 22, 2006.

Where are Sonoma Pharmaceuticals, Inc.'s principal executive offices located?

The principal executive offices are located at 5445 Conestoga Court, Suite 150, Boulder, CO 80301.

What is the Standard Industrial Classification (SIC) code for Sonoma Pharmaceuticals, Inc.?

The SIC code for Sonoma Pharmaceuticals, Inc. is 3841, which corresponds to SURGICAL & MEDICAL INSTRUMENTS & APPARATUS.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on March 25, 2025 regarding Sonoma Pharmaceuticals, Inc. (SNOA).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing